Vidac Pharma Holding (STU:T9G) EBIT: €-1.66 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:T9G Vidac Pharma Holding PLC STU:T9G
21 GF Score
Price €0.42
! 2 Warning Signs
View Full Analysis

What is Vidac Pharma Holding EBIT?

Vidac Pharma Holding STU:T9G +1.94% 21 EBIT is €-1.66 Mil as of Jun. 2025. GuruFocus rates STU:T9G with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Vidac Pharma Holding's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2025 was €-0.88 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was €-1.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vidac Pharma Holding's annualized ROC % for the quarter that ended in Jun. 2025 was -401.37%. Vidac Pharma Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -43,800.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vidac Pharma Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -7.05%.

Vidac Pharma Holding  (STU:T9G) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vidac Pharma Holding's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-1.752 * ( 1 - 0% )/( (0.466 + 0.407)/ 2 )
=-1.752/0.4365
=-401.37 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.564 - 0.887 - ( 0.531 - max(0, 1.349 - 0.56+0.531))
=0.466

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.816 - 0.972 - ( 0.788 - max(0, 1.376 - 0.813+0.788))
=0.407

Note: The Operating Income data used here is two times the semi-annual (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Vidac Pharma Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.752/( ( (0.004 + max(-0.934, 0)) + (0.004 + max(-1.007, 0)) )/ 2 )
=-1.752/( ( 0.004 + 0.004 )/ 2 )
=-1.752/0.004
=-43,800.00 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.029 + 0 + 0) - (0.887 + 0 + 0.076)
=-0.934

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.015 + 0 + 0.0099999999999999) - (0.972 + 0 + 0.06)
=-1.007

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vidac Pharma Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=-1.656/23.475
=-7.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding EBIT Related Terms

Vidac Pharma Holding EBIT Historical Data

* Premium members only.

The historical data trend for Vidac Pharma Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding EBIT Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EBIT
0.00 -0.70 -1.41 -1.59

Vidac Pharma Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBIT Get a 7-Day Free Trial -0.54 -0.87 -0.80 -0.78 -0.88

STU:T9G vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, Vidac Pharma Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's EV-to-EBIT falls into.


STU:T9G
21GF Score
Vidac Pharma Holding PLC STU:T9G
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vidac Pharma Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-1.66 Mil mean?
Vidac Pharma Holding (STU:T9G) has a EBIT of €-1.66 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vidac Pharma Holding.
Is Vidac Pharma Holding's EBIT too high?
Vidac Pharma Holding's current EBIT is €-1.66 Mil. Overall, Vidac Pharma Holding has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Vidac Pharma Holding's EBIT compare to VRTX and REGN?
Vidac Pharma Holding's EBIT of €-1.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vidac Pharma Holding. Vidac Pharma Holding's current EBIT is €-1.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vidac Pharma Holding stock overvalued right now?
Vidac Pharma Holding (STU:T9G) has a current EBIT of €-1.66 Mil. The current EBIT is €-1.66 Mil. Vidac Pharma Holding's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vidac Pharma Holding (STU:T9G), the current EBIT is €-1.66 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vidac Pharma Holding Business Description

Other Exchanges T9G:Germany
Address 20-22 Wenlock Road, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines for oncologic and onco-dermatologic diseases. The company's research targets the modification of the tumor microenvironment to inhibit cancer cell growth by selectively affecting metabolic checkpoints in cancer cells without harming normal tissue. Its drug pipeline includes candidates such as VDA-1102 ointment, VDA-1102 IV, and VDA-1275, which are designed to treat conditions like Actinic Keratosis and Cutaneous T-cell Lymphoma. Vidac Pharma operates internationally with headquarters in London and aims to treat cancer through novel chemical entities.
21GF Score

Get the complete analysis for STU:T9G

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price